Open Access
How to translate text using browser tools
1 October 1998 ICI 182,780 Stimulates the Growth of a Uterine Cell Line Derived from p53-Deficient Mice
Makoto Hanazono, Kengo Moro, Eriko Nakagawa, Yasuhiro Tomooka
Author Affiliations +
Abstract

UE8 is a uterine epithelial cell line established from p53-deficient fetal female mice. UE8 exhibits a typical epithelial morphology in culture and is strongly positive for cytokeratin, but negative for vimentin in immunocytochemistry. UE8 shows an active growth in a phenol red free 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's nutrient mixture F-12 supplemented with 3% heat-inactivated and dextran-coated charcoal-treated fetal calf serum. Both immunocytochemistry and immunoblot analyses confirmed that UE8 was negative for the estrogen receptor. Diethylstilbestrol added to the medium at concentrations between 10−6 and 10−8 M had no significant effect on the proliferative rate, and estradiol-17β at 10−6 M was slightly inhibitory. Unexpectedly, however, the“pure anti-estrogen”ICI 182,780 at 10−6 M significantly enhanced cell proliferation. This is the first observation that the“pure anti-estrogen”ICI 182,780 stimulates the growth of uterine epithelial cells without estrogen receptors.

INTRODUCTION

The development of pure anti-estrogens without estrogenic activity may be important in the relief of a variety of clinical problems. For this purpose, suitable in vitro models are needed to estimate the quality of the proposed agents. MCF-7 (Osborne et al., 1987) and Ishikawa (Nishida et al., 1985) cells, whose proliferation was stimulated by estrogen, have been utilized to estimate the quality of anti-estrogens with conflicting results. For example, tamoxifen is an antagonist for the growth of MCF-7 cells (Katzenellenbogen et al., 1987; Wakeling et al., 1989; Pratt and Pollak, 1993), but it is a full agonist for the growth of Ishikawa cells (Kleinman et al., 1996). Therefore, a variety of cell lines may be necessary to estimate with certainty the side effects of newly-developed reagents.

The mouse uterus is a particularly sensitive indicator of the agonist activity of anti-estrogens (Clark and Markaverich, 1982; Furr and Jordan, 1984). However, its usage is hampered by failure to establish estrogen-sensitive cell lines except for the m-M116 cells established from a leiomyoma of a CaBP9k/Tag transgenic mouse (Blin et al., 1996). Recently, we have succeeded in establishing uterine cell lines from p53-deficient mice (Hanazono et al., 1997). Throughout the characterization of these cell lines, we found that one of the lines showed a proliferative response to the pure anti-estrogen ICI 182,780.

MATERIALS AND METHODS

Cell culture and passaging

UE8 was maintained in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's nutrient mixture F-12 without phenol red (DMEM/F12; Sigma, St. Louis, MO, USA) containing 3% (v/v) heatinactivated fetal calf serum (FCS; Commonwealth Serum Laboratories, Melbourne, Australia), supplemented with penicillin (31 μg/ml, Sigma), streptomycin (50 μg/ml, Sigma) and Fungizone (2.5 μg/ml, Life Technologies, Grand Island, New York, USA). When cells became confluent, they were washed with Ca2+- and Mg2+-free phosphate-buffered saline (PBS) and then incubated in trypsin solution at room temperature for 2 min. After the incubation, cells were removed from dishes by pipetting, and one-fortieth of them were passaged. They were continually cultured and passaged more than 140 times. Cells used in the present study were at passage between 140 and 160.

Immunocytochemical staining

The method of immunocytochemical staining was described previously (Hanazono et al., 1997). In brief, cells in a small volume of cell suspension were seeded on Lab Tek tissue culture chamber slides (Miles Labs., Naperville, IL, USA) and incubated in the medium with estradiol-17β (E2, 10−8 M) for 3 days. Cells grown on the slides were fixed in 95% (v/v) ethanol containing 1% (v/v) acetic acid at 0°C for 1 hr. After rinsing with ethanol (99%; v/v), the slides were placed in 95% ethanol and then immersed in PBS.

After pre-incubation in PBS containing 5% (v/v) normal goat serum (NGS; Zymed Lab., San Francisco, CA, USA) and 1% (w/v) bovine serum albumin (BSA; Sigma) to block non-specific binding of antibody, cells were covered with anti-estrogen receptor (ER) monoclonal antibody (AER314, 1/50; NeoMarkers, Fremont, CA, USA), and incubated for 8 hr. After washing, cells were incubated with FITCconjugated anti-mouse IgG serum (Biosource International, Camarillo, CA, USA). On control slides, incubation with the primary antibody was omitted. Immunoreactivity was examined with a fluorescence microscope (BH2-RFK, Olympus Optical Ind., Tokyo, Japan).

Cell and tissue extracts

When cells became confluent in a 100-mm dish, cells were collected in a tube and washed once in PBS. Then 2 ml 0.5 M Tris buffer (pH 7.6) containing 150 mM NaCl, 10 mM EDTA, 20 mM NaF, 0.25 mM phenylmethylsulfonylfluoride (Sigma), 1% (v/v) TritonX-100 (Sigma), 1% (w/v) Na-deoxycholate (Sigma) and 0.1% (w/v) sodium dodecyl sulfate (SDS; Sigma) were added to the tube and incubated at 0°C for 20 min before collecting the lysate.

An adult CD-1 female mouse was killed by cervical dislocation and the uteri were dissected out. The tissues were minced and suspended in 1 ml 0.08 M Tris buffer (pH 6.9) containing 0.11 M SDS and 0.1 M dithiothreitol (Sigma) (Bentvelsen et al., 1996). The suspension was homogenized in an ice-cold glass homogenizer. The homogenate was sonicated for 10 sec and immediately incubated at 95°C for 5 min. The homogenate was centrifuged for 30 min at 2 × 105 × g and the supernatant was collected. Protein concentration of the samples for blotting analysis was determined using BioRad Protein Assay (Bio-Rad, Richmond, CA, USA). Aliquots of all samples were stored at −80°C until analysis.

Analysis of blotting

The samples were electrophoresed on SDS-polyacrylamide-slab gel and electrophoretically transferred onto polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). Membranes were rinsed in Tris-buffered saline (TBS; pH 7.6) for 15 min. The membranes were blocked with 10% (w/v) skimmed milk (Yukijirushi-Nyuugyou Co., Sapporo Japan) in TBS-0.05% (v/v) Tween 20 (TBS-T) at 4°C for overnight and incubated with anti-ER antibody (1/50; NeoMarkers). The antibody was diluted with 5% (w/v) skimmed milk in TBS-T, which was also used to wash the membranes. They were incubated with horseradish peroxidase-conjugated antibody (Biosource) for 1 hr. Then they were washed twice with TBS-T containing 5% skimmed milk and once with TBS-T, and reacted with an enhanced chemiluminescence detection regent (ECL; Amersham, Buckinghamshire, England) at room temperature for 1 min. Autographs of chemiluminescence were prepared by exposing the membranes for 30 sec to X-ray film (Kodak) at room temperature.

Effects of estrogens and ICI 182,780 on growth

UE8 cells were trypsinized, collected and washed three times in PBS. Then the cells were plated on 96-well dishes (5 × 103 cells/well) in DMEM/F12 containing 3% (v/v) FCS treated with dextran-coated charcoal (DCCFCS) to remove steroids. ICI 182,780 (a generous gift from Dr. C. Mackay, ICI Pharmaceuticals, Cheshire, England) was added to the medium at 10−6 or 10−7 M, and the cells were cultured for 1, 3 and 5 days. Media were changed every 2 days. E2 and diethylstilbestrol (DES; Sigma) were dissolved in absolute ethanol and added to the medium at 10−6, 10−7, or 10−8 M. Ethanol vehicle (0.01%; v/v) was added to control cultures. Cells were cultured for 3 days, and then they were incubated in 100 μl DMEM/F12 containing 10% (v/v) alamar Blue™ (Biosource) for 3 hr; cell numbers per well were estimated by the amount of dye reduction. The absorbance of the reduced products, which was measured spectrophotometrically by a microplate reader, was proportional to the number of cells (r2 = 0.99). Student's t-test was used for statistical analysis.

RESULTS

Sensitivity to estrogens and detection of ER

To examine the effect of estrogens on UE8 cell proliferation, growth rates were monitored in 3% DCCFCS with increasing concentrations of E2 or DES. As shown in Fig. 1, these estrogens had no stimulating effect on UE8 cells. E2 slightly inhibited cell proliferation at 10−6 M.

Fig. 1

Estrogen sensitivity of UE8. To determine estrogen stimulation of UE8 cell proliferation, growth rates were monitored in DMEM/F12 containing 3% DCCFCS. Cells were cultured for 3 days with increasing concentrations of E2 or DES (10−8, 10−7 and 10−6 M). Control cultures (C) were grown in medium with ethanol vehicle (0.01%). Cell numbers per well were estimated by alamar Blue assay. Data are expressed as % of control growth (the mean ± SEM; n = 5). ∗, p < 0.01 vs. control.

i0289-0003-15-5-737-f01.gif

Immunocytochemistry did not reveal ER in UE8 cells (data not shown), and this result was further confirmed by Western blotting. An intact mouse uterus as a positive control contained ER as a strong single band at 66 kDa. (Fig. 2, lane a), but extract of UE8 cells did not contain any detectable immunoreactive band (Fig. 2, lane b).

Fig. 2

Blotting profile of estrogen receptor (ER). Lane a: extract of mouse uterus (30 μg). Lane b: extract of UE8 (30 μg). ER in mouse uterus was detectable as a single band, but UE8 did not contain any specific immunoreactive band.

i0289-0003-15-5-737-f02.gif

Sensitivity to ICI 182,780

ICI 182,780 was first tested on the cells in medium containing 3% DCCFCS. Proliferation was slightly stimulated by ICI 182,780 at 10−7 M: 20% over the control (p < 0.01, Fig. 1) on day 5 of culture. A higher concentration (10−6 M) resulted in further growth stimulation: 31% on day 1, 47% on day 3 and 45% on day 5 over controls (p < 0.01, Fig. 3).

Fig. 3

Effect of ICI 182,780 in DCCFCS-supplemented medium. Cells were plated on 96-well dishes (5 × 103 cells/well) in DMEM/F12 containing 3% DCCFCS. ICI 182,780 was added at 10−6 M (solid bars) or 10−7 M (striped bars). Control cultures (open bars) were grown in medium with ethanol vehicle (0.01%). Media were changed every 2 days. At 1, 3, 5 days, cell numbers per well were estimated by alamar Blue assay. Data are expressed as % of day 1 control growth (mean ± SEM; n = 5). ∗, p < 0.01 vs. control value for each day.

i0289-0003-15-5-737-f03.gif

DISCUSSION

The mouse uterus is a particularly sensitive indicator of agonist activity of anti-estrogens (Clark and Markaverich, 1982; Furr and Jordan, 1984) and has been widely used in vivo to estimate activity of estrogen antagonists. Establishment of cell lines from the uterus may allow to determine whether an antagonist acts as a pure anti-estrogen or not. Furthermore, cell lines are critical for investigation of the molecular mechanisms of antagonist action. In the present study, we reported that the proliferation of UE8 cells was stimulated by a“pure antiestrogen”ICI 182,780, but inhibited by E2 at 10−6 M. However, both immunocytochemical and immunoblot analyses revealed no detectable ER in these cells. The same results were obtained from another line UE2 which was co-established with UE8 (data not shown). This is the first observation that the“pure anti-estrogen”ICI 182,780 can stimulate the growth of uterine cells in vitro.

Our present observations raise an interesting question: whether the proliferation of UE8 cells was stimulated through ER. The growth of ER-positive MCF-7 cells is inhibited by ICI 182,780, but that of ER-negative BT-20 cells is not affected by the anti-estrogen (Wakeling and Bowler, 1992). Although neither immunocytochemistry nor immunoblot analysis demonstrated that UE8 cells have detectable ER, it is possible that the monoclonal antibody employed in the present study might be unable to recognize ER, because the p53-deficiency may cause conformational changes due to a greatly increased rate of accumulation of genetic mutations (Kastan et al., 1992). In LNCaP prostate tumor cells, a mutated steroid receptor was reported: the cells have a point mutation in the androgen receptor at the androgen-binding domain, and their proliferation was stimulated not only by androgens but also by antiandrogens, estrogens and progesterone (Veldscholte et al., 1990, 1992). Therefore, it is possible that the anti-estrogen stimulates proliferation through mutated ER which lost immunoreactivity to the anti-ER antibody. As shown in Fig. 2, E2 at 10−6 M caused growth inhibition of UE8 cells; such inhibition is also reported in primary cultures of mouse uterine epithelial cells (Uchima et al., 1991), eventhough DES had no effect on the proliferation.

Alternatively, the anti-estrogen (or its possible contaminants) may stimulate the proliferation of UE8 cells without involving ER; DES or its metabolites can have effects through some macromolecules of ER-negative cells (Barrett et al., 1981). ICI 182,780 or its metabolites may also stimulate the proliferation of UE8 cells through a non-ER mechanism. In addition, Kuiper et al. (1996) cloned a novel rat ER (ERβ), which has low homology of its N-terminal with that of the previously cloned ER (recently renamed ERα). They reported that MCF-7 cells do not contain ERβ, whereas two types of ER (α and β) are expressed in rat and human uterus (Kuiper et al., 1997). Although additional studies are needed to clarify the mechanism how the anti-estrogen stimulates cell proliferation without the ER, UE8 is an unique cell line to investigate estrogen-regulated proliferation.

Acknowledgments

The authors are greatly indebted to Prof. N. Shimizu, Third Department of Internal Medicine, Teikyo University School of Medicine, Ichihara Hospital for his continuous help, encouragement and valuable advice. We also thank to Prof. Howard A. Bern, University of California at Berkeley for his critical reading of the manuscript. This work was supported by Special Coordination Funds for Promoting Science and Technology of the Agency of Science and Technology of Japan to Y. T.

REFERENCES

1.

J. C. Barrett, A. Wong, and J. A. McLachlan . 1981. Diethylstilbestrol induces neoplastic transformation without measurable gene mutation at two loci. Science 212:1402–1404. Google Scholar

2.

F. M. Bentvelsen, M. J. McPhaul, C. M. Wilson, J. D. Wilson, and F. W. George . 1996. Regulation of immunoreactive androgen receptor in the adrenal gland of the adult rat. Endocrinology 137:2659–2663. Google Scholar

3.

C. Blin, F. L'Horset, B. Romagnolo, S. Colnot, M. Lambert, M. Thomasset, A. Kahn, A. Vandewalle, and C. Perret . 1996. Functional and growth properties of a myometrial cell line derived from transgenic mice: effects of estradiol and antiestrogens. Endocrinology 137:2246–2253. Google Scholar

4.

J. H. Clark and B. M. Markaverich . 1982. The agonistic-antagonistic properties of clomiphene: a review. Pharmac Ther 15:467–519. Google Scholar

5.

B. J. A. Furr and V. C. Jordan . 1984. The pharmacology and clinical uses of tamoxifen. Pharmac Ther 25:127–205. Google Scholar

6.

M. Hanazono, K. Hirabayashi, H. Tomisawa, S. Aizawa, and Y. Tomooka . 1997. Establishment of uterine cell lines from p53-deficient mice. In Vitro Cell Dev Biol Anim 33:668–671. Google Scholar

7.

M. B. Kastan, Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace Jr . 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587–597. Google Scholar

8.

B. S. Katzenellenbogen, K. L. Kendra, M. J. Norman, and Y. Berthois . 1987. Proliferation, hormonal responsiveness, and estrogen receptorcontent of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47:4355–4360. Google Scholar

9.

D. Kleinman, M. Karas, M. Danilenko, A. Arbeli, C. T. Roberts Jr, D. LeRoith, J. Levy, and Y. Sharoni . 1996. Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol. Endocrinology 137:1089–1095. Google Scholar

10.

G. G. J. M. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, and J-A. Gustafsson . 1996. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925–5930. Google Scholar

11.

G. G. J. M. Kuiper, B. Carlsson, K. Grandien, E. Enmark, J. Häggblad, S. Nilsson, and J-A. Gustafsson . 1997. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138:863–870. Google Scholar

12.

M. Nishida, K. Kasahara, M. Kaneko, H. Iwasaki, and K. Hayashi . 1985. Establishment of a new human endometrial adenocarcinoma cell line, containing estrogen and progesterone receptors. Acta Obstet Gynecol Jpn 37:1103–1111. Google Scholar

13.

C. K. Osborne, K. Hobbs, and J. M. Trent . 1987. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Tr 9:111–121. Google Scholar

14.

S. E. Pratt and M. N. Pollak . 1993. Estrogen and antiestrogen modulation of MCF 7 human breast cancer cell proliferation is associated with specific alteration in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 53:5193–5198. Google Scholar

15.

F-D. A. Uchima, M. Edery, T. Iguchi, and H. A. Bern . 1991. Growth of mouse endometrial luminal epithelial cells in vitro: functional integrity of the oestrogen receptor system and failure of oestrogen to induce proliferation. J Endocrinol 128:115–120. Google Scholar

16.

J. Veldscholte, C. Ris-Stalpers, G. G. J. M. Kuiper, G. Jenster, C. Berrevoets, E. Claassen, H. C. J. van Rooij, J. Trapman, A. O. Brinkmann, and E. Mulder . 1990. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534–540. Google Scholar

17.

J. Veldscholte, C. A. Berrevoets, A. O. Brinkmann, J. A. Grootegoed, and E. Mulder . 1992. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31:2393–2399. Google Scholar

18.

A. E. Wakeling, E. Newboult, and S. E. Peters . 1989. Effect of antioestrogens on the proliferation of MCF-7 human breast cancer cells. J Molec Endocr 2:225–234. Google Scholar

19.

A. E. Wakeling and J. Bowler . 1992. ICI 182,780, a new antioestrogen with clinical potential. J Steroid Biochem Molec Biol 43:173–177. Google Scholar
Makoto Hanazono, Kengo Moro, Eriko Nakagawa, and Yasuhiro Tomooka "ICI 182,780 Stimulates the Growth of a Uterine Cell Line Derived from p53-Deficient Mice," Zoological Science 15(5), 737-740, (1 October 1998). https://doi.org/10.2108/zsj.15.737
Received: 17 December 1997; Accepted: 1 April 1998; Published: 1 October 1998
Back to Top